CrossMark

The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health

Christopher A. Lowry[1] · David G. Smith[1] · Philip H. Siebler[1] · Dominic Schmidt[1] ·
Christopher E. Stamper[1] · James E. Hassell Jr.[1] · Paula S. Yamashita[1] · James H. Fox[1] ·
Stefan O. Reber[2] · Lisa A. Brenner[3,4] · Andrew J. Hoisington[5] ·
Teodor T. Postolache[6,7,8] · Kerry A. Kinney[9] · Dante Marciani[10] · Mark Hernandez[11] ·
Sian M. J. Hemmings[12] · Stefanie Malan-Muller[12] · Kenneth P. Wright[1] · Rob Knight[13] ·
Charles L. Raison[14] · Graham A. W. Rook[15]

Abstract The hygiene or "Old Friends" hypothesis proposes that the epidemic of inflammatory disease in modern urban societies stems at least in part from reduced exposure to microbes that normally prime mammalian immunoregulatory circuits and suppress inappropriate inflammation. Such diseases include but are not limited to allergies and asthma; we and others have proposed that the markedly reduced exposure to these Old Friends in modern urban societies may also increase vulnerability to neurodevelopmental disorders and stress-related psychiatric disorders, such as anxiety and affective disorders, where data are emerging in support of inflammation as a risk factor. Here, we review recent advances in our understanding of the potential for Old Friends, including environmental microbial inputs, to modify risk for inflammatory disease, with a focus on neurodevelopmental and psychiatric conditions. We highlight potential mechanisms, involving bacterially derived metabolites, bacterial antigens, and helminthic antigens, through which these inputs promote immunoregulation. Though findings are encouraging, significant human subjects' research is required to evaluate the potential impact of Old Friends, including environmental microbial inputs, on biological signatures and clinically meaningful mental health prevention and intervention outcomes.

This article is part of the topical collection on *Early Life Environmental Health*

✉ Christopher A. Lowry
  christopher.lowry@colorado.edu

[1] Department of Integrative Physiology and Center for Neuroscience, University of Colorado Boulder, 1725 Pleasant Street, Boulder, CO 80309-0354, USA

[2] Laboratory for Molecular Psychosomatics, Clinic for Psychosomatic Medicine and Psychotherapy, University of Ulm, D-89081 Ulm, Germany

[3] Departments of Psychiatry, Physical Medicine & Rehabilitation, University of Colorado, Anschutz School of Medicine, Aurora, CO 80045, USA

[4] Rocky Mountain Mental Illness Research Education and Clinical Center (MIRECC), Veterans Integrated Service Network (VISN) 19, Denver, CO 80220, USA

[5] Department of Civil and Environmental Engineering, United States Air Force Academy, Colorado Springs, CO 80840, USA

[6] University of Maryland School of Medicine, Baltimore, MD, USA

[7] Rocky Mountain MIRECC, Denver, CO 80220, USA

[8] VISN 5 MIRECC, Baltimore, MD 21201, USA

[9] Civil, Architectural and Environmental Engineering, University of Texas Austin, Austin, TX 78712, USA

[10] Qantu Therapeutics, Inc., Lewisville, TX 75057, USA

[11] Department of Civil, Environmental and Architectural Engineering, University of Colorado Boulder, Boulder, CO 80309, USA

[12] Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town 7505, South Africa

[13] Departments of Pediatrics and Computer Science and Engineering, and Center for Microbiome Innovation, University of California San Diego, La Jolla, CA 92093, USA

[14] School of Human Ecology and School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA

[15] Center for Clinical Microbiology, UCL (University College London), WC1E 6BT, London, UK

Introduction

It is firmly established that inflammation can play a causative
role in psychiatric disorders [reviewed in [1•]. Here, we sum-
marize major points from the human data, but there is also a
mass of animal data that falls outside the scope of this review.
Raised levels of cytokines are found in the blood and cerebro-
spinal fluid (CSF) of a subset of cases of depression and psy-
chosis [1•, 2, 3], and raised expression is found in the brains of
those who die by suicide [1•]. Moreover, depression is asso-
ciated with polymorphisms of inflammatory cytokine genes
[4], and the risk alleles tend to have inflammatory functions
within the immune system [5]. The known environmental risk
factors are also pro-inflammatory [6]. Recently, using non-
invasive positron emission tomography (PET) scans, it has
been possible to confirm that there is activation of microglia
(tissue-resident macrophages in the central nervous system
(CNS)) in depressed and in psychotic subjects [7, 8]. Very
direct evidence for the contributory role of inflammation
comes from the observation that some patients become de-
pressed when treated with interferon alpha, an inflammatory
cytokine [9]. Finally, anti-inflammatory treatments such as
inhibitors of cyclooxygenase or a neutralizing antibody to
tumor necrosis factor (TNF) are therapeutic in those patients
who have raised inflammatory biomarkers [10•, 11]; the same
subset tends to be resistant to conventional antidepressants
[12]. Finally, it has been shown in rodents and monkeys that
inflammation occurring during pregnancy can lead to abnor-
malities of brain development and behavior that are reminis-
cent of autism or schizophrenia [13, 14], while epidemiolog-
ical findings suggest that the same is true in humans [15].

A second class of evidence that inflammation can play a
causative role in psychiatric disorders comes from studies of
the pathways that link peripheral inflammation to changes in
CNS function [1•]. Cytokines can (1) access the brain via the
circumventricular organs where there is a reduced blood-brain
barrier, (2) be transported into the brain by specific transport
mechanisms, or (3) cause inflammatory changes in the cells of
the blood-brain barrier [16]. Other signals are transmitted via
the vagus nerve which, in response to inflammatory signals in
the periphery, drives cytokine release in the CNS [16].
Peripheral inflammation also activates enzymes such as
indoleamine 2,3-dioxygenase that convert tryptophan to N-
formylkynurenine, which is then converted to kynurenine.
Kynurenine is raised in the plasma of depressed suicide
attempters [17], and following entry into the brain, it is con-
verted into several metabolites with potent neuropsychiatric
effects [18]. Meanwhile, peripheral TNF somehow drives
brain microglia to secrete chemokine (C-C motif) ligand 2

(CCL2; also referred to as monocyte chemoattractant protein
1 (MCP1), which attracts monocytes into the brain [19].

Against this background, we now consider how microbial
exposures, including environmental microbial exposures, in-
fluence the regulation of our immune systems in the context of
the effects of inflammation on CNS function.

The "Old Friends" Hypothesis and Mental Health

The epidemic of inflammatory disease, including allergy and
asthma, in modern urban societies is increasing dramatically,
but underlying biological mechanisms are still unexplained.
The hygiene or Old Friends hypothesis proposes that this ep-
idemic is due at least in part to reduced exposure to environ-
mental microorganisms that normally prime immunoregulato-
ry circuits and suppress inappropriate inflammation [20]. We
and others have proposed that reduced exposure to these Old
Friends in modern urban societies may increase vulnerability
to neurodevelopmental disorders (including autism spectrum
disorder (ASD), schizophrenia) and stress-related psychiatric
disorders such as anxiety and mood disorders [21–37, 38••].
Exaggerated inflammation is emerging as an important risk
factor in all of these disorders [21–37, 38••].
Immunoregulation, measured as a balanced expansion of ef-
fector T cell (also called helper T (Th) cell) populations and
regulatory T cells (Treg), is known to be driven by microbial
signals. These signals originate mainly from organisms with
which mammals co-evolved, including (1) the symbiotic mi-
crobiota residing in the cutaneous and mucosal surfaces (e.g.,
surfaces of the upper airways, lungs, and gastrointestinal
tract); (2) pathogens associated with the "Old Infections"
(for example, helminths) that were present throughout life in
evolving human hunter-gatherer populations; and (3) organ-
isms from the natural environment with which humans were
inevitably in daily contact through inhalation or ingestion (and
so had to be tolerated by the immune system) [25].
Immunoregulation is thought to be compromised in developed
countries because of reduced contact with these three catego-
ries of organisms that are necessary for regulation, in the same
way that removal of other reliably experienced developmental
resources such as sunlight or vitamins cause a range of phys-
iological problems [25]. Here, we explore our rapidly
expanding understanding of the potential role for compro-
mised immunoregulation in allergies, neurodevelopmental
disorders, and stress-related psychiatric disorders, and the di-
verse mechanisms through which exposure to the Old Friends
may increase immunoregulation and suppress inappropriate
inflammation.

Comorbidity of Allergy, Anxiety, and Affective Disorders

The hygiene hypothesis originated in the epidemiologic stud-
ies of allergy. As originally envisaged by Strachan [39], the

hygiene hypothesis proposed that lower incidence of infection in early childhood could be an explanation for the rapid rise in allergic diseases, such as asthma and hay fever, documented during the twentieth century. Allergic or atopic disorders including allergic rhinitis, allergic asthma, eczema, and food allergies are prevalent and potentially disabling conditions [40]. These disorders are all increasing in prevalence in developed countries [40]. The Old Friends hypothesis was proposed to emphasize that we no longer believe that exposure to childhood infections or outright pathogens per se is beneficial but rather that lack of exposure to symbiotic organisms, as well as the Old Infections, is harmful [20]. Indeed, hygiene is important for the prevention of serious infections. Epidemiological and clinical studies report a high incidence of anxiety and increased levels of emotional reactivity in individuals suffering from allergies [41–46]. This comorbidity is evidenced by the fact that the incidence of anxiety disorders among individuals with allergies is more than double with respect to the general population [41, 44, 47, 48]. Moreover, studies in mice report that intranasal (i.n.) or aerosolized allergen exposure in sensitized animals results in the activation of limbic brain regions and anxiety-like behavioral responses [49, 50]. While these studies have not quantified normalized antigenic exposures from airborne allergens, they suggest a strong association between allergy and anxiety disorders, consistent with a potential role for inadequate immunoregulation and exaggerated inflammation in both conditions.

Inadequate Immunoregulation as a Risk Factor for Neurodevelopmental and Neuropsychiatric Disorders

Results from animal models and clinical studies are consistent with the idea that inadequate immunoregulation increases risk for development of neurodevelopmental disorders, including ASD [51••, 52, 53, 54•]. Elevated serum levels of the pro-inflammatory cytokine, interleukin-17A (IL-17A; produced by IL-17-expressing T cells, called Th17 cells, as well as a number of families of innate lymphoid cells (ILCs)) [55], have been noted in children with autism and were furthermore associated with symptom severity [53]. Th17 cells are involved in infection, autoimmunity, and inflammation, especially in skin or mucosal surfaces of the lungs and gut [56, 57]. A Th17 bias may emerge during fetal development, as recent studies in mice have shown that maternal retinoic acid receptor-related orphan nuclear receptor γt (RORγt)-dependent Th17 cells and IL-17A mediate abnormal cortical development and an autism-like phenotype of offspring in a maternal immune activation model [51••].

Importantly, for the thesis of this review, recent studies have demonstrated that the gut microbiota has the capacity to induce a specific population of Treg, the RORγt$^+$ subset of Treg [58••, 59]. Loss of RORγ$^+$ (there are two isoforms of RORγ, RORγt and RORγ) Tregs results in enhanced

production of IL-17 and interferon-γ in the colons of otherwise unchallenged mice, and increases in chemically induced colitis, indicating a decreased ability of colonic Tregs lacking RORγ to regulate inflammatory responses [58••]. In germ-free mice, introduction of specific bacterial species is sufficient to increase RORγ$^+$ Tregs to levels observed in their conventionally raised specific pathogen-free counterparts [58••]. Thus, Choi and colleagues [51••] argue that therapeutic targeting of Th17 cells in vulnerable pregnant mothers may reduce the risk of bearing children with inflammation-dependent ASD-like phenotypes, and specific immunoregulatory bacteria have the ability to shift the balance of RORγ$^+$ T cells from a Th17 to a Treg bias. A window of vulnerability may coincide with a predicted window of time during the late second trimester and early third trimester associated with increased risk of autism following maternal infections [60], maternal exposures to stressors [61], and maternal exposures to environmental pollutants [62]. This time frame coincides with a critical window of Treg development in the fetus, including the emergence, seeding, and expansion of Treg populations and Th17 cells (from 12 weeks of gestation until early postnatal development, with some continued development out to 2 years of age) [63]. Together with the finding that maternal stress is associated with an infant microbiota with a biological signature of increased potential for inflammation [64], immunoregulatory or anti-inflammatory approaches may have value for both prevention and treatment of ASD. Consistent with this hypothesis, treatment with the anti-inflammatory flavonoid, luteolin, results in a significant improvement in functioning in children with ASD [65], in association with decreases in plasma concentrations of biomarkers of inflammation [66].

Alterations in T cell number and function have also consistently been detected in patients with schizophrenia [67]. Researchers have subsequently proposed that maternal immune activation, induced by intrauterine infection and additional factors, could facilitate the preferential generation of Th17 cells and subsequent priming of neuroinflammatory processes, ultimately contributing to the neuroprogression in schizophrenia [68]. A meta-analysis found that treatment with nonsteroidal anti-inflammatory drugs (NSAID) could be a potential treatment strategy to reduce symptom severity in schizophrenia [69]. Recent non-human primate studies using first and second trimester infection with a viral mimic of double-stranded RNA have demonstrated behavioral abnormalities in offspring resembling both ASD and schizophrenia [70, 71]. Further, abnormal neuronal dendritic formations were characterized in association with the behavioral changes observed in the non-human primate model of maternal immune activation [72], suggesting developmental changes in offspring associated with inadequate immunoregulation during pregnancy. Thus, an argument can be made supporting a role for inflammatory insults, particularly Th17-driven

inflammation in the skin or mucosal surfaces of the lungs and gut, as risk factors for neurodevelopmental and neuropsychiatric disorders. Furthermore, an argument can be made that prophylactic exposure of the mother to Treg-promoting and Th17-reducing commensal or environmental bacteria may reduce that risk.

Inadequate Immunoregulation as a Risk Factor for Stress-Related Mental Health Disorders

Human and animal studies are consistent with the hypothesis that inadequate immunoregulation increases the risk for development of stress-related psychiatric disorders [25, 73•, 74•]. That is, chronic low-grade inflammation (a potential consequence of chronic infection, psychosocial stress, trauma, exposure to environmental pollutants or toxins, autoimmune processes, chronic allergy) is associated with increased risk for mental disorders [75, 76]. In prospective studies, high baseline plasma concentration of C-reactive protein (CRP; an acute-phase protein and pattern recognition receptor that is induced in response to inflammation), measured before deployment in military personnel, was associated with increased likelihood of posttraumatic stress disorder (PTSD) symptoms after deployment, suggesting that inflammation before trauma exposure may predispose individuals to PTSD symptoms [73•]. Similar findings were evident in a gene expression study in soldiers pre- and post-deployment [77], where results indicated that genes involved in networks of innate immunity and interferon signaling are overexpressed in PTSD cases predeployment, suggesting causality [77]. Furthermore, increased circulating levels of the pro-inflammatory cytokine IL-6 immediately following trauma exposure predict the later development of PTSD symptoms [78]. Although not confirmed in all studies, low-grade inflammation has been associated with PTSD, as indicated by elevated serum CRP, IL-1β, and IL-6 [79–81]. Moreover, patients with PTSD show enhanced spontaneous secretion of IL-1β, IL-6, and TNF by isolated peripheral blood mononuclear cells, which correlates with symptom severity [82, 83]. Consistent with these findings, subjects with PTSD also have higher risk for autoimmune disease, including inflammatory bowel disease and rheumatoid arthritis [84], while genome-wide association studies in PTSD cohorts have revealed association with *ANKRD55* [85], a gene associated with several autoimmune and inflammatory disorders, including multiple sclerosis [86, 87], type 2 diabetes mellitus [88], celiac disease [89], and rheumatoid arthritis [90].

Similar findings have been documented for developing depressive symptoms. For example, a study of over 3000 individuals showed that elevated baseline plasma CRP or IL-6 predicted cognitive symptoms of depression measured 12 years later [91]. Moreover, in a study published early in 2014, elevated plasma concentrations of IL-6 in 9-year-old

children predicted depressive symptoms measured at age 18 [92]. Therefore, it is reasonable that exposures to immunoregulatory or anti-inflammatory bacteria may be useful for the prevention or treatment of symptoms of PTSD or major depression. Consistent with this hypothesis, the anti-inflammatory glucocorticoid hydrocortisone decreases the risk of subsequent PTSD if administered immediately after trauma exposure [93]. Furthermore, treatment of depressed patients with standard antidepressants plus an anti-inflammatory compound was reported to decrease depressive symptoms more than antidepressants with a placebo [11, 94].

Old Friends with Immunoregulatory Potential

The previous paragraphs show how anxiety and affective disorders are comorbid with chronic inflammatory conditions and are epidemiologically linked to persistent inflammation, even in the absence of any clinically apparent inflammatory condition. The latter situation is an evidence of failing immunoregulation. Similarly, we also described how failing immunoregulation during pregnancy, in animals and humans, can lead to neurodevelopmental problems in the fetus mediated by excessive inflammation. We now discuss, within each of the microbiological categories that constitute the Old Friends, the organisms that have been shown to have immunoregulatory properties that might be exploited for prevention of, or as therapies for, psychiatric conditions.

Commensal or Mutualistic Microorganisms with Immunoregulatory Potential

Much of the focus on the interface between the human microbiome and potential positive human health outcomes has been put on commensal or mutualistic organisms, particularly those associated with the gut microbiome. Two recent studies have shed light on the potential for symbiotic gut microorganisms to influence immunoregulatory circuits [58••, 59]. These two studies demonstrated that the gut microbiota induces expansion of a specific subset of cells, known as the RORγt$^+$ Treg in the lamina propria of the gastrointestinal tract. They then used chemical inhibitors and genetic manipulation to block the function of these Treg and demonstrated that they have broad anti-inflammatory effects in several models of colitis. They also noted that this cell type is severely depleted in germ-free or antibiotic-treated mice [58••, 59]. However, reconstituting the gut microbiota could restore expansion of these Treg. Importantly, oral administration of a single microbial species was sufficient to increase the frequency of RORγt$^+$ Treg within the colon of germ-free mice, in some cases to levels observed in specific pathogen-free control mice, which have a typical microbiota.

Commensal bacteria that increase RORγt⁺ Treg include several species belonging to the phylum Firmicutes, a phylum with a large number of probiotic species, to include *Clostridium histolyticum*, *Clostridium ramosum*, *Enterococcus faecium*, *Lactobacillus casei*, *Lactobacillus rhamnosus*, and *Staphylococcus saprophyticus*. However, species from other phyla were also effective, including *Bifidobacterium breve* (Actinobacteria), *Bacteroides thetaiotaomicron* and *Parabacteroides johnsonii* (Bacteroidetes), *Fusobacterium mortiferum* and *Fusobacterium nucleatum* (Fusobacteria), and *Acinetobacteria lwoffi* (Proteobacteria). As mentioned above, loss of RORγ⁺ Tregs results in enhanced production of colonic IL-17 and interferon-γ and increases in chemically induced colitis, indicating a decreased ability of colonic Tregs lacking RORγ to regulate inflammatory responses [58••]. Thus, commensal bacteria from diverse phyla have the capacity to induce Treg (Table 1). Many of these same probiotic species have been shown to have stress-protective and mental health benefits in rodent and human studies (Table 1). The mechanisms through which bacteria from such diverse phyla can induce immunoregulatory pathways are not clear, but a number of candidate mechanisms are discussed below.

Old Infections with Immunoregulatory Potential

A number of old infections can induce immunoregulation. For example, humans co-evolved with *Helicobacter pylori* for tens of thousands of years. *H. pylori* is found in higher abundance in rural Papua New Guineans [95] and was recently found in previously uncontacted Amazonian Amerindians [96], as well as in the 5300-year old Iceman [97]. *H. pylori* is potently immunoregulatory and consequently has protective effects in allergy and chronic inflammatory disorders [98, 99]. Additional Old Infections include infections with Hepatitis A virus (HAV), *Toxoplasma gondii* (*T. gondii*), *Salmonella*, gut helminths and blood nematodes, and *Mycobacterium tuberculosis* [6, 100]. A common feature of many of these Old Infections is that they bind the C-type lectin receptor, dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN; also referred to as cluster of differentiation 209 (CD209)) on dendritic cells (DC), in many cases using the receptor to gain entry into immune cells and subvert the host immune response [101–106]. Interactions between Old Infections and DC-SIGN can induce immunoregulatory responses [102, 105], and the central feature of pathogens that can interact with DC-SIGN is that they cause chronic infections that can last a lifetime, persistence that is often dependent on a suppression of Th1 and concomitant shift to Th2 immunity [104].

Environmental Microorganisms with Immunoregulatory Potential

In addition to commensal and mutualistic microorganisms and the Old Infections, environmental microorganisms also induce immunoregulation following their ingestion [107] or inhalation [108, 109]. These organisms have been referred to as "pseudocommensals" because they would have been present in large numbers throughout mammalian evolution, even if they do not colonize the gut [20, 110]. Our understanding of the Old Friends hypothesis has been informed by studies using heat-inactivated and viable environmental bacteria, particularly soil-derived bacteria belonging to the genus *Mycobacterium*, which can be viewed as a case study of the potential for environmental microorganisms to influence immunoregulatory circuits and prevent inflammatory disease [111]. While it has long been believed that mycobacteria are not normally present in the human microbiome or the built environment in developed countries, recent studies reveal that a broad spectrum of *Mycobacteria* spp. are systemic residents of operating metropolitan water distribution systems [112, 113]. To what extent these and other microbes impact humans through common infrastructure exposures, however, remains unknown. Another recent study has defined the hidden "non-tuberculous mycobacteriome," with approximately 50 prevalent and abundant mycobacterial operational taxonomic units, in the nostrils, buccal mucosa, oropharynx, and dental plaque of healthy subjects [114•], a distribution that may reflect the environmental origin of these microorganisms. Together, (1) disruption of the commensal microbes, (2) a reduction in Old Infections, and (3) diminished contact with immunoregulatory environmental microbes have the potential to increase vulnerability to allergic and inflammatory disorders, as well as mental health disorders, where chronic inflammation is emerging as an associated risk factor.

Diverse Molecular Mechanisms Through Which Old Friends Induce Anti-inflammatory and Immunoregulatory Effects

Bacterially Derived Metabolites that Induce Immunoregulatory Responses

Tryptophan and Bacterially and Host-Derived Tryptophan Metabolites

Evidence suggests that commensal bacteria are important for the extraction, synthesis, or absorption of some amino acids, including tryptophan. In particular, plasma

Table 1 Immunoregulatory microorganisms with beneficial effects in mental health studies

Phylum/microorganism	Model	Environmental sources	Mental health relevant findings	Immunoregulation
Actinobacteria				
Mycobacterium vaccae	Human	Environmental saprophyte (soil, mud, water, grasses, decaying organic matter) [156–162]	Increased cognitive function, decreased pain in patients with advanced non-small-cell lung cancer [152]	↑DCreg [163]
	Mouse		Activation of brain serotonergic systems and antidepressant-like behavioral effects [164]; decreased anxiety/increased cognitive function [165]	↑Treg [111]
			Promotion of proactive behavioral responses to psychosocial stress; prevention of stress-induced colitis and stress-induced exaggeration of chemically induced colitis; reduction of anxiety-like behavior in stressed mice [153•]	
Bifidobacterium breve	Mouse	Human commensal	Increased cognitive function [166]; decreased anxiety-related behaviors [167]	↑$ROR\gamma^{+}$ Helios^{-} Treg [58••]
Bifidobacterium infantis	Rat	Human commensal	Reversal of depressive-like behavior following maternal separation [168]	↑Treg [169]
Bifidobacterium longum	Human	Human commensal	Decreased anxiety and depressive symptoms in healthy volunteers (administered with *L. helveticus*) [149, 170]	
	Mouse		Decreased-colitis associated anxiety [171, 172]; increased cognitive function (1714) [166]; decreased stress, anxiety- and depression-related behaviors [167]	↑Treg and functional Treg responses [173]
Bacteroidetes				
Bacteroides fragilis	Mouse	Human commensal	Developmental protection from some of the behavioral symptoms associated with autism spectrum disorder [54•]	↑Treg [174]
Firmicutes				
Clostridium butyricum	Human	Endospore-forming soil bacterium	Anxiolytic effects [150]	
Enterococcus faecium	Mouse	Human commensal, wetlands [175]	Increased brain antioxidant markers [176]	
Lactobacillus casei	Human	Human commensal, fermented foods [177]	Improvement in anxiety symptoms in patients with chronic fatigue syndrome [178]; improved mood [179]	
			Decreased perceived stress in medical students preparing for a nationwide exam [151]	
Lactobacillus fermentum	Rat	Human commensal, raw vegetables [180], fermented foods [177, 181]	Decreased anxiety and inhibition of antibiotic-induced cognitive impairment [182]	↑Treg [183]
Lactobacillus helveticus	Human	Fermented foods [177]	Decreased anxiety and depressive symptoms in healthy volunteers (administered with *B. longum*) [149, 170]; increased cognitive function [184]	↑$ROR\gamma^{+}$ Helios^{-} Treg [58••]

Table 1 (continued)

Phylum/microorganism	Model	Environmental sources	Mental health relevant findings	Immunoregulation
	Rat		Improved cognitive function, decreased anxiety-related behavior [185]; prevention of stress-induced cognitive impairment and anxiety- and depressive-like responses [186]	
	Mouse		Decreased anxiety-related behavior [187]; improved cognitive function, decreased anxiety-related behavior (administered with L. rhamnosus) [188, 189]	↑Treg (with L. rhamnosus) [190]
Lactobacillus pentosus	Mouse	Fermented foods [177]	Improved cognitive function [191]	
Lactobacillus reuteri	Human	Human commensal, fermented foods [177]	Increased workplace healthiness [192]	↑Treg [193]
Lactobacillus rhamnosus	Mouse	Human commensal, fermented foods [177]	Vagus nerve dependent alterations in GABA receptor mRNA expression in brain, reduced anxiety- and depression-related behavior [194]; improved cognitive function, decreased anxiety-related behavior (administered with L. helveticus) [188, 189]	↑$ROR\gamma^{+}$ Helios^{-} Treg [58••]; ↑Treg (with L. helveticus) [190]

Immunoregulatory probiotics that induce $ROR\gamma^{+}$ Helios^{-} Tregs, but have not been tested in the context of mental health, F. mortiferum, A. lwoffii, F. nucleatum, P. johnsonii, C. histolyticum, B. thetaiotaomicron, S. saprophyticus, C. ramosum [58••]

Adapted from Hoisington et al. [31], with permission

tryptophan and N-acetyltryptophan concentrations in conventionally reared mice are 40 and 60 % lower, respectively, compared to germ-free mice [115], suggesting that the gut microbiota plays an important role in the metabolism of tryptophan. A subset of gut bacteria expresses tryptophanase, an enzyme that converts tryptophan to indole, pyruvate, and ammonia. Meanwhile, it is becoming increasingly clear that tryptophan and diverse tryptophan metabolites (both bacterially derived and host-derived) have immunomodulatory effects. Tryptophan influences proliferation of T cells by regulating passage through the gap 1 (G1) phase of the cell cycle [116]. Tryptophan depletion, secondary to activation of indoleamine-2,3-dioxygenase, regulates immune tolerance of the fetus and regulates immune responses in models of skin allograft rejection, tumor growth and autoimmune encephalomyelitis [117], and chemically induced colitis [118]. The tryptophan metabolite melatonin induces Treg via actions on melatonin receptors (MT_1) [119]. Interactions between bacterially driven and host-driven tryptophan metabolism are important for host defense. For example, $CD4^+$ T cells defend against certain pathogens, including *Chlamydia* and *Leishmania*, by starving the pathogens of tryptophan. In those cases, tryptophan starvation works well, since those pathogens are natural tryptophan auxotrophs (lack the ability to synthesize tryptophan). *M. tuberculosis*, on the other hand, is capable of synthesizing tryptophan, and it is protected from this mechanism of host defense; a small molecule inhibitor of *M. tuberculosis* tryptophan synthesis turns *M. tuberculosis* into an auxotroph and restores the efficacy of host-mediated tryptophan depletion [120]. Perhaps just as important, even probiotic species such as *Lactobacillus* spp. are capable of tryptophan biosynthesis and metabolism and generate tryptophan metabolites that activate the aryl hydrocarbon receptor (Ahr), resulting in immunoregulation and mucosal protection from damage [121]. Immunoregulatory bacterially derived tryptophan metabolites that serve as Ahr agonists include tryptamine, indol-3-acetaldehyde, indole-3-acetic acid, indole-3-aldehyde, and kynurenine [121]. Other bacterially derived tryptophan metabolites that interact with Ahr include indole, 3-methyl-indole, indoxyl sulfate, 6-formylindolo[3,2b] carbazole, and kynurenic acid [122]. Activation of Ahr can either induce functional Treg cells that suppress inflammation or enhance Th17 cell differentiation and increase inflammation, depending on the specific nature of the agonist [123, 124]. Specifically, Ahr induces RORγt$^+$ Tregs [125], consistent with studies discussed above demonstrating that specific species within the gut microbiota can induce RORγt$^+$ Tregs and mucosal immune tolerance [58••, 59]. Thus, the microbiota, acting via synthesis of tryptophan and generation of

tryptophan metabolites that interact with Ahr, regulates both Treg and Th17 cell differentiation in a ligand-specific fashion, constituting a unique target for therapeutic immunomodulation.

Short-Chain Fatty Acids

Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are produced by bacteria in the gut during fermentation of insoluble fiber from dietary plant matter [126]. SCFAs support the growth of probiotic *Bifidobacterium* and *Lactobacillus* species. Furthermore, SCFAs have anti-inflammatory effects by regulating the release of cytokines and chemokines from immune cells [127–129]. Of particular importance, propionate and acetate can directly induce colonic Tregs and their suppressive capacity via activation of G protein-coupled receptor (GPCR) 43, encoded by the free fatty acid receptor 2 gene (*Ffar2*) [130, 131]. This is one of the primary routes by which *Clostridia* affect Treg populations [132]. Furthermore, butyrate, which is also a metabolite of *Clostridia* species, potentiates DCs to induce Treg through inhibition of histone deacetylase (HDAC) and may induce epigenetic changes [132].

Microbial Molecules That Induce Immunoregulatory Responses

A number of bacterial antigens have been identified that increase immunoregulatory circuits, predominantly by interactions with the pattern recognition receptor (PRR) DC-SIGN on DCs. DC-SIGN ligation interferes with toll-like receptor-mediated inflammatory responses, resulting in decreases in nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) signaling, decreases in IL-6, TNF, and IL-12, concurrently with increases in IL-10 [102]. Activation of DC-SIGN in DCs may be a common mechanism through which bacterial antigens derived from the Old Friends bias T cell differentiation toward a Treg phenotype (Table 1). Examples of such molecules, together with their sources, receptors, and mode of action are listed in Table 2.

Other Immunoregulatory Molecules From Old Infections

In addition to the heterogeneous group of molecules described above, there is mounting interest in microbial products that imitate the Lewis^X trisaccharide motif (Fig. 1).

Lewis-X$^+$ Lipopolysaccharide

The lipopolysaccharide (LPS) Lewis (Le) antigens of *H. pylori* are able to bind DC-SIGN in gastric DCs and block Th1 development [104, 105]. Conversely, Le$^-$

Table 2 Microbial molecules that induced immunoregulatory responses

Molecule	Source	Receptor	Actions
Polysaccharide A (PSA)	*Bacteroides fragilis*	Unclear in mice, DC-SIGN on human DC [195]	Expands Treg population [196]
Surface layer protein A (SlpA)	*Lactobacillus acidophilus*	DC-SIGN	Induces more IL-10 and less IL-12 p70 [197]
Mannose-capped lipoarabinomannan	*Mycobacterium tuberculosis*	Mannose receptor (MR), dectin-2, DC-SIGN, TLR2 [102, 198, 199]	Expands Treg through a prostaglandin E2-dependent mechanism [200]
60 kDa chaperonin-1 (Cpn60.1); heat shock 60 kDa protein (Hsp60)	*M. tuberculosis* and homologous molecules from microbiota [201]	DC-SIGN, TLR2 and others?	Expands Treg [202–205]
DnaK; also known as Hsp70, GroP, GrpF, Seg	*M. tuberculosis* and homologous molecules from microbiota	DC-SIGN and others? [201]	Drives immunoregulatory pathways? [205]
Glyceraldehyde-3 phosphate dehydrogenase (GAPDH)	Mycobacteria and homologous molecules from microbiota [206]	DC-SIGN [201]	Reduces pro-inflammatory cytokines and chemokines [207]
Lipoarabinomannan carrier protein LprG	*M. tuberculosis*	DC-SIGN [201]	Binds to triacylated glycolipids and increases their agonist activity at TLR2 [102, 208]
Lewis-X+ lipopolysaccharide (LPS)	*Helicobacter pylori*	DC-SIGN [104, 105]	Drives Treg responses [99].
Lewis-X+ soluble egg antigen (SEA)	*Schistosoma mansoni*	DC-SIGN [138]	Drives expansion of Th2 and Treg responses [104, 133]

H. pylori induce strong Th1 responses [104, 105]. Although the specific mechanisms are not clear, *H. pylori* potently drives Treg responses [99].

A Lewis X trisaccharide

B Lacto-N-fucopentaose III (LNFPIII)

Fig. 1 Structures of the Lewis^X trisaccharide motif **(a)** and its helminth-derived analogue lacto-N-fucopentaose III (LNFPIII) **(b)**

Helminthic Parasite Antigens

The Lewis-X+ soluble egg antigen (SEA) from the helminthic parasite *Shistosoma mansoni* binds DC-SIGN and induces expansion of Th2 and Treg responses [104, 133]. Sole Th2 anti-inflammatory immunomodulators apparently emerged when metazoan parasites invaded vertebrates. Indeed, Th2 immunity may have been developed as a repair response to tissue and organ damage resulting from inflammatory processes directed toward relatively large parasites like helminths [134]. Hence, to prevent an inflammatory Th1 immunity, parasitic helminths produced compounds that mimic those that the host makes to avert inflammatory responses that would interfere with tissue healing or cause fetal rejection in mammals; agents that, besides inducing Th2, inhibit, but do not abrogate, Th1 immunity [135]. The main family of helminth-derived immunomodulators contains, as a pharmacophore, the sugar fucose (Fuc); these immunomodulators, which are glycans, structurally and functionally imitate the Lewis^X trisaccharide motif, like lacto-N-fucopentaose III (LNFPIII), a Lewis^X-containing immunomodulatory glycan found in human milk [136, 137] and SEA from *S. mansoni* (Fig. 1a, b). The sugar Fuc is rare in both vertebrates and bacteria and is involved in ontogenesis and some immunological functions, like acting as a Th2 immune modulator. The

success of the immunological mimicry developed by helminths is shown by the long-term relationship between the parasite and its host. Fucosylated glycans exert their sole Th2 immune modulatory effects by binding to DC-SIGN, which binds oligosaccharides carrying either mannosyl or fucosyl residues [138]. Any inflammation induced by parasite infection must be tightly regulated, and evidence suggests that this function is mediated by induction of Treg by diverse parasites [139].

Membranous Cells Transfer Intact Gut Microorganisms From the Bronchopulmonary and Intestinal Lumens and Present Them to Antigen-Presenting Cells

In order for bacterial antigens, such as the glycans described above, to influence DC function and induce immunoregulatory responses, it is necessary for the bacteria to have direct contact with antigen-presenting cells, raising the question of how bacteria in the airways or gastrointestinal tract come into direct contact with these cells. Antigen-presenting cells, e.g., alveolar macrophages and CD11c$^+$ DCs, are common in the airways [140], but host mechanisms also ensure that microorganisms in both the airways and gastrointestinal tract can be transferred from the airway or gastrointestinal tract lumen into the body for presentation to antigen-presenting cells. This function is performed in part by microfold or membranous cells (M cells), which are found in both the airways and gastrointestinal tract. M cells in the airways have been documented as entry sites for M. tuberculosis in mice [141]. Similar reports have been made for M cell recognition of mycobacteria in the gastrointestinal tract. Regarding studies involving oral inoculation with mycobacteria, Fujimura wrote that in "1-hour post-inoculated specimens, bacteria were found adhering specifically to M cells, and the microfolds of the M cells were seen to stretch like tentacles toward the bacteria and to catch them." [142]. Mycobacteria are translocated into the M cells and are subsequently presented to the mucosal macrophages and DCs [142]. Although we have focused primarily on the mucosal membranes of the airways and gastrointestinal tract, evidence suggests an important dialogue between the skin microbiota and immune function as well, which should be explored further [143–145].

Anti-inflammatory and Immunoregulatory Interventions

Anti-inflammatory agents such as inhibitors of cyclooxygenase or a neutralizing antibody to TNF are significantly therapeutic in those patients who have raised inflammatory biomarkers [10•, 11]. Can we therefore exploit the anti-inflammatory properties of immunoregulation-inducing microorganisms? Extensive investigation of animal models has shown that

administration of immunoregulatory probiotics and some other manipulations of the microbiota have profound effects on the development and function of the brain. This work has been reviewed recently and will not be described here [146••, 147], though examples where microbial agents were used in therapeutic models are given in Table 1. Human studies are rare, but there is direct evidence that large doses of probiotics can modulate the human brain. Women were given a milk product fermented with a complex mixture of probiotics twice daily for 4 weeks [148••]. Magnetic resonance imaging was used before and after the intervention to measure resting brain activity and the brain response to images of emotional faces. Compared to subjects who had not taken the probiotic, changes in the intrinsic activity of the resting brain and in the emotional response were demonstrated [148••]. In another randomized, double-blind, placebo-controlled study, it was found that when normal volunteers consumed a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) for 30 days, anxiolytic effects were detected by several validated questionnaires [149]. In a very recent study, Clostridium butyricum or placebo was administered orally every morning and evening from 2 weeks before laryngectomy. Hamilton anxiety scores of placebo recipients increased as the surgery approached, but these scores decreased in those taking the probiotic [150]. Finally, recent studies in humans demonstrate that administration of the immunoregulatory probiotic, Lactobacillus casei, for 8 weeks reduced gastrointestinal symptoms and decreased perceived stress in medical students preparing for a standardized exam [151].

However, as we make clear in this review, orally ingested probiotics are not the only possible approach. An environmental soil saprophyte already known to induce Treg in mice [24] was tried as an immunotherapeutic in a human cancer trial [152]. While there was no prolongation of survival, it was noted that immunotherapy recipients had improved cognitive functioning and emotional health [152]. More recently, the same organism, administered subcutaneously as a killed preparation, has been tested in an animal model where exposure to chronic psychosocial stress induces expansion of Helicobacter spp. [153•], pathobionts, that are known to induce colitis in individuals with inadequate immunoregulation [154, 155]. Pre-immunisation with the environmental saprophyte blocked stress-induced colitis, blocked stress-induced exaggeration of chemically induced colitis, and reduced anxiety-related behaviors in stressed mice. Remarkably, these effects were dependent upon the induction of Treg [153•].

Conclusions

Exaggerated inflammation is emerging as a risk factor for neurodevelopmental and neuropsychiatric disorders, such as ASD and schizophrenia, and stress-related psychiatric

disorders, including PTSD and major depression. Anti-inflammatory interventions have shown some promise in treating these conditions. Meanwhile, there is increasing evidence that the microbiota associated with mucosal membranes in the airways and gastrointestinal tract have potential for anti-inflammatory and long-term immunoregulatory effects on the host immune system. Thus, bioimmunomodulatory approaches hold promise for the prevention and treatment of these disorders. Here, we have highlighted the potential mechanisms through which the microbiota, including microbial inputs from the environment, may elicit anti-inflammatory and immunoregulatory responses. The evidence suggests that both bacterial metabolites and bacterial and helminthic antigens have potential for anti-inflammatory and immunoregulatory effects that may have value in the prevention and/or treatment of neurodevelopmental, neuropsychiatric, and stress-related mental health disorders.

Compliance with Ethical Standards

Conflict of Interest David G. Smith, Philip H. Siebler, Dominic Schmidt, Christopher E. Stamper, James E. Hassell Jr., Paula S. Yamashita, James H. Fox, Stefan O. Reber, Lisa A. Brenner, Andrew J. Hoisington, Teodor T. Postolache, Kerry A. Kinney, Dante Marciani, Mark Hernandez, Sian M.J. Hemmings, Stefanie Malan-Muller, Rob Knight, Charles L. Raison, and Graham A.W. Rook report that they have no conflict of interest. Christopher A. Lowry serves on the scientific advisory board of Immodulon Therapeutics Ltd. Kenneth P. Wright serves on the scientific advisory board of Torvec Inc., and has research grants from Torvec, Inc. and Philips Inc.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance

1.• Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22–34. **This study outlines the current evidence for inflammation in the etiology and pathophysiology of depression and the rationale for anti-inflammatory and immunoregulatory approaches to treatment of depression**.

2. Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics:meta-analysis and implications. Mol Psychiatry. 2016;21:554–64.

3. Maes M, Ombelet W, Libbrecht I, Stevens K, Kenis G, De Jongh R, et al. Effects of pregnancy and delivery on serum concentrations of Clara Cell Protein (CC16), an endogenous anticytokine: lower serum CC16 is related to postpartum depression. Psychiatry Res. 1999;87:117–27.

4. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav Immun. 2013;31:31–47.

5. Raison CL, Miller AH. The evolutionary significance of depression in pathogen host defense (PATHOS-D). Mol Psychiatry. 2013;18:15–37.

6. Rook GA, Lowry CA, Raison CL. Hygiene and other early childhood influences on the subsequent function of the immune system. Brain Res. 1617;2014:47–62.

7. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. Am J Psychiatry. 2016;173:44–52.

8. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268–75.

9. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643–52.

10.• Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatmentresistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41. **This study shows that treatment with an antibody targeting TNF can be beneficial in a subset of depressed patients with increased inflammation**.

11. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–91.

12. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane VA, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25:1532–43.

13. Willette AA, Lubach GR, Knickmeyer RC, Short SJ, Styner M, Gilmore JH, et al. Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. Behav Brain Res. 2011;219:108–15.

14. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27:10695–702.

15. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res. 2011;69:26R–33.

16. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun. 2007;21:727–35.

17. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun. 2011;25:1272–8 Curr Envir Health Rpt.

18. Bryleva EY, Brundin L. Kynurenine pathway metabolites and suicidality. Neuropharmacology. 2016. doi:10.1016/j.neuropharm.2016.01.034.

19. D'Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor alpha signaling during peripheral organ inflammation. J Neurosci. 2009;29:2089–102.

20. Rook GA, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol. 2004;25:237–55.

21. Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry. 2010;67:1211–24.

22. Rook GA, Lowry CA. The hygiene hypothesis and psychiatric disorders. Trends Immunol. 2008;29:150–8.

23. Rook GA, Raison CL, Lowry CA. Can we vaccinate against depression? Drug Discov Today. 2012;17:451–8.

24. Rook GA, Lowry CA, Raison CL. Microbial 'Old Friends', immunoregulation and stress resilience. Evol Med Public Health. 2013;2013:46–64.

25. Rook GA, Raison CL, Lowry CA. Microbial 'Old Friends', immunoregulation and socioeconomic status. Clin Exp Immunol. 2014;177:1–12.

26. Rook GA, Raison CL, Lowry CA. Microbiota, immunoregulatory Old Friends and psychiatric disorders. Adv Exp Med Biol. 2014;817:319–56.

27. Rook GA, Lowry CA, Raison CL. Hygiene and other early childhood influences on the subsequent function of the immune system. Brain Res. 2015;1617:47–62.

28. Rook GAW, Lowry CA. The hygiene hypothesis and affective and anxiety disorders. In: Rook GAW, editor. The hygiene hypothesis and Darwinian medicine, vol. 1. Basel: Birkhauser Publishing; 2009.

29. Rook GAW, Raison CL, Lowry CA. Childhood microbial experience, immunoregulation, inflammation and adult susceptibility to psychosocial stressors and depression in rich and poor countries. Evol Med Public Health. 2013;2013:14–7.

30. Rook GAW, Raison CL, Lowry CA. In: Heidt PJ, Midtvedt T, Rusch V, Versalovic J, editors. Microbial "Old Friends", immunoregulation and psychiatric disorders. Old Herborn University Press; 2013. p. 61–90. Old Herborn University Monograph, vol. 26.

31. Hoisington AJ, Brenner LA, Kinney KA, Postolache TT, Lowry CA. The microbiome of the built environment and mental health. Microbiome. 2015;3:1–12.

32. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part I—autointoxication revisited. Gut Pathog. 2013;5:5.

33. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III—convergence toward clinical trials. Gut Pathog. 2013;5:4.

34. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part II—contemporary contextual research. Gut Pathog. 2013;5:3.

35. Logan AC. Dysbiotic drift: mental health, environmental grey space, and microbiota. J Physiol Anthropol. 2015;34:23.

36. Logan AC, Katzman MA, Balanza-Martinez V. Natural environments, ancestral diets, and microbial ecology: is there a modern "paleo-deficit disorder"? Part II. J Physiol Anthropol. 2015;34:9.

37. Logan AC, Jacka FN, Craig JM, Prescott SL. The microbiome and mental health: looking back, moving forward with lessons from allergic diseases. Clin Psychopharmacol Neurosci. 2016;14:131–47.

38.•• Williamson LL, McKenney EA, Holzknecht ZE, Belliveau C, Rawls JF, Poulton S, et al. Got worms? Perinatal exposure to helminths prevents persistent immune sensitization and cognitive dysfunction induced by early-life infection. Brain Behav Immun. 2016;51:14–28. **This study demonstrates that exposure of breeding dams and their offspring to helminths prevents microglial sensitization and cognitive dysfunction in offspring following early life infection with E. coli**.

39. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax. 2000;55 Suppl 1:S2–10.

40. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454:445–54.

41. Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc. 2007;28:393–7.

42. Blaiss MS. Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008;29:1–6.

43. Buske-Kirschbaum A, Ebrecht M, Kern S, Gierens A, Hellhammer DH. Personality characteristics in chronic and nonchronic allergic conditions. Brain Behav Immun. 2008;22:762–8.

44. Chida Y, Hamer M, Steptoe A. A bidirectional relationship between psychosocial factors and atopic disorders: a systematic review and meta-analysis. Psychosom Med. 2008;70:102–16.

45. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28:3–9.

46. Wright RJ. Stress and atopic disorders. J Allergy Clin Immunol. 2005;116:1301–6.

47. Goodwin RD, Fergusson DM, Horwood LJ. Asthma and depressive and anxiety disorders among young persons in the community. Psychol Med. 2004;34:1465–74.

48. Goodwin RD. Self-reported hay fever and panic attacks in the community. Ann Allergy Asthma Immunol. 2002;88:556–9.

49. Palermo-Neto J, Guimaraes RK. Pavlovian conditioning of lung anaphylactic response in rats. Life Sci. 2000;68:611–23.

50. Tonelli LH, Katz M, Kovacsics CE, Gould TD, Joppy B, Hoshino A, et al. Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. Brain Behav Immun. 2009;23:784–93.

51.•• Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351:933–9. **This study shows that IL-17A from the mother mediates development of an autism-like phenotype in a mouse model of maternal infection**.

52. Mostafa GA, Al SA, Fouad NR. Frequency of CD4+ CD25high regulatory Tcells in the peripheral blood of Egyptian children with autism. J Child Neurol. 2010;25:328–35.

53. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin-17A in children with autism. J Neuroinflammation. 2012;9:158.

54.• Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–63. **This study shows that exposure to immunoregulatory bacteria early in development can prevent some aspects of an autism-like phenotype in a mouse model of maternal infection**.

55. Sutton CE, Mielke LA, Mills KH. IL-17-producing $\gamma\delta$ T cells and innate lymphoid cells. Eur J Immunol. 2012;42:2221–31.

56. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008;453:1051–7.

57. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013;8:477–512.

58.•• Sefik E, Geva-Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM, et al. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science. 2015;349:993–7. **This study shows that individual species of immunoregulatory bacteria can restore RORγ+ Treg in germ-free mice**.

59. Ohnmacht C, Park JH, Cording S, Wing JB, Atarashi K, Obata Y, et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORgammat(+) T cells. Science. 2015;349:989–93.

60. Brown AS. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol. 2012;72:1272–6.

61. Beversdorf DQ, Manning SE, Hillier A, Anderson SL, Nordgren RE, Walters SE, et al. Timing of prenatal stressors and autism. J Autism Dev Disord. 2005;35:471–8.

62. Raz R, Roberts AL, Lyall K, Hart JE, Just AC, Laden F, et al. Autism spectrum disorder and particulate matter air pollution before, during, and after pregnancy: a nested case–control analysis within the Nurses' Health Study II cohort. Environ Health Perspect. 2015;123:264–70.

63. Dietert RR, Dietert JM. Potential for early-life immune insult including developmental immunotoxicity in autism and autism spectrum disorders: focus on critical windows of immune vulnerability. J Toxicol Environ Health B Crit Rev. 2008;11:660–80.

64. Zijlmans MA, Korpela K, Riksen-Walraven JM, de Vosb WM. Maternal prenatal stress is associated with the infant intestinal microbiota. Psychoneuroendocrinology. 2015;53:233–45.

65. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35:592–602.

66. Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with autism spectrum disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL-6. Transl Psychiatry. 2015;5, e647.

67. Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:993–9.

68. Debnath M, Berk M. Th17 pathway - mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull. 2014;40:1412–21.

69. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal antiinflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73:414–9.

70. Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol Psychiatry. 2014;75:332–41.

71. Machado CJ, Whitaker AM, Smith SE, Patterson PH, Bauman MD. Maternal immune activation in nonhuman primates alters social attention in juvenile offspring. Biol Psychiatry. 2015;77:823–32.

72. Weir RK, Forghany R, Smith SE, Patterson PH, McAllister AK, Schumann CM, et al. Preliminary evidence of neuropathology in nonhuman primates prenatally exposed to maternal immune activation. Brain Behav Immun. 2015;48:139–46.

73.• Eraly SA, Nievergelt CM, Maihofer AX, Barkauskas DA, Biswas N, Agorastos A, et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry. 2014;71:423–31. **This study shows that elevated plasma CRP predicts subsequent risk for development of PTSD.**

74.• Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci U S A. 2014;111:16136–41. **This study demonstrates that individual differences in peripheral immune status, particularly LPS-induced release of IL-6, predict individual variability in development of anxiety and depressive-like behavioral responses to a subsequent psychosocial stressor in mice.**

75. Kivimaki M, Shipley MJ, Batty GD, Hamer M, Akbaraly TN, Kumari M, et al. Long-term inflammation increases risk of common mental disorder: a cohort study. Mol Psychiatry. 2014;19: 149–50.

76. Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom Med. 2014;76:181–9.

77. Breen MS, Maihofer AX, Glatt SJ, Tylee DS, Chandler SD, Tsuang MT, et al. Gene networks specific for innate immunity define posttraumatic stress disorder. Mol Psychiatry. 2015;20:1538–45.

78. Pervanidou P, Kolaitis G, Charitaki S, Margeli A, Ferentinos S, Bakoula C, et al. Elevated morning serum interleukin (IL)-6 or evening salivary cortisol concentrations predict posttraumatic stress disorder in children and adolescents six months after a motor vehicle accident. Psychoneuroendocrinology. 2007;32:991–9.

79. Spitzer C, Barnow S, Volzke H, Wallaschofski H, John U, Freyberger HJ, et al. Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: evidence from the general population. J Psychiatr Res. 2010;44:15–21.

80. Heath NM, Chesney SA, Gerhart JI, Goldsmith RE, Luborsky JL, Stevens NR, et al. Interpersonal violence, PTSD, and inflammation: potential psychogenic pathways to higher C-reactive protein levels. Cytokine. 2013;63:172–8.

81. Baker DG, Nievergelt CM, O'Connor DT. Biomarkers of PTSD: neuropeptides and immune signaling. Neuropharmacology. 2012;62:663–73.

82. Andrews JA, Neises KD. Cells, biomarkers, and post-traumatic stress disorder: evidence for peripheral involvement in a central disease. J Neurochem. 2012;120:26–36.

83. Gola H, Engler H, Sommershof A, Adenauer H, Kolassa S, Schedlowski M, et al. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry. 2013;13:40.

84. O'Donovan A, Cohen BE, Seal KH, Bertenthal D, Margaretten M, Nishimi K, et al. Elevated risk for autoimmune disorders in Iraq and Afghanistan veterans with posttraumatic stress disorder. Biol Psychiatry. 2014;77:365–74.

85. Stein MB, Chen C-Y, Ursano RJ, Cai T, Gelernter J, Heeringa SG, et al. Genome-wide association studies of posttraumatic stress disorder in 2 cohorts of US Army soldiers. JAMA Psychiatry. 2016;E1–10. Published online May 11, 2016.

86. Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, et al. Genome-wide significant association of ANKRD55rs6859219 and multiple sclerosis risk. J Med Genet. 2013;50:140–3.

87. Alloza I, Otaegui D, de Lapuente AL, Antiguedad A, Varade J, Nunez C, et al. ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. Genes Immun. 2012;13:253–7.

88. Harder MN, Ribel-Madsen R, Justesen JM, Sparso T, Andersson EA, Grarup N, et al. Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased beta-cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity in the Danish Inter99 cohort. J Clin Endocrinol Metab. 2013;98:E801–6.

89. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011;7, e1002004.

90. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis. 2012;71:1984–90.

91. Gimeno D, Kivimaki M, Brunner EJ, Elovainio M, De VR, Steptoe A, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39:413–23.

92. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1121–8.

93. Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2014;7, CD006239.

94. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:79–85.

95. Martinez I, Stegen JC, Maldonado-Gomez MX, Eren AM, Siba PM, Greenhill AR, et al. The gut microbiota of rural Papua New Guineans: composition, diversity patterns, and ecological processes. Cell Rep. 2015;11:527–38.

96. Clemente JC, Pehrsson EC, Blaser MJ, Sandhu K, Gao Z, Wang B, et al. The microbiome of uncontacted Amerindians. Sci Adv. 2015;1:1–12.

97. Maixner F, Krause-Kyora B, Turaev D, Herbig A, Hoopmann MR, Hallows JL, et al. The 5300-year-old Helicobacter pylori genome of the iceman. Science. 2016;351:162–5.

98. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, et al. Helicobacter pylori infection prevents allergic asthma inmousemodels through the induction of regulatory Tcells. J Clin Invest. 2011;121:3088–93.

99. Arnold IC, Hitzler I, Muller A. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol. 2012;2:10.

100. Rook GAW, Raison CL, Lowry CA. Microbes and mood: a new approach to the therapy of depression? Microbiologist. 2011;32–6.

101. Gillespie L, Roosendahl P, Ng WC, Brooks AG, Reading PC, Londrigan SL. Endocytic function is critical for influenza Avirus infection via DC-SIGN and L-SIGN. Sci Rep. 2016;6:19428.

102. Vergne I, Gilleron M, Nigou J. Manipulation of the endocytic pathway and phagocyte functions by Mycobacterium tuberculosis lipoarabinomannan. Front Cell Infect Microbiol. 2014;4:187.

103. Smits HH, Hartgers FC, Yazdanbakhsh M. Helminth infections: protection from atopic disorders. Curr Allergy Asthma Rep. 2005;5:42–50.

104. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003;3:697–709.

105. Bergman MP, Engering A, Smits HH, van Vliet SJ, van Bodegraven AA, Wirth HP, et al. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J Exp Med. 2004;200:979–90.

106. Appelmelk BJ, van Die I, van Vliet SJ, Vandenbroucke-Grauls CM, Geijtenbeek TB, van Kooyk Y. Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J Immunol. 2003;170:1635–9.

107. Hunt JR, Martinelli R, Adams VC, Rook GA, Brunet LR. Intragastric administration of Mycobacterium vaccae inhibits severe pulmonary allergic inflammation in a mousemodel. Clin Exp Allergy. 2005;35:685–90.

108. Moore MN. Do airborne biogenic chemicals interact with the PI3K/Akt/mTOR cell signalling pathway to benefit human health and wellbeing in rural and coastal environments? Environ Res. 2015;140:65–75.

109. Rook GA. Regulation of the immune system by biodiversity from the natural environment: an ecosystem service essential to health. Proc Natl Acad Sci U S A. 2013;110:18360–7.

110. Rook GAW. Introduction: The changing microbial environment, Darwinian medicine and the hygiene hypothesis. In: Rook GAW, editor. The hygiene hypothesis and Darwinian medicine. Basel: Birkhäuser; 2009. p. 1–27.

111. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med. 2002;8:625–9.

112. Holinger EP, Ross KA, Robertson CE, Stevens MJ, Harris JK, Pace NR. Molecular analysis of point-of-use municipal drinking water microbiology. Water Res. 2014;49:225–35.

113. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci U S A. 2009;106:16393–9.

114.• Macovei L, McCafferty J, Chen T, Teles F, Hasturk H, Paster BJ, et al. The hidden 'mycobacteriome' of the human healthy oral cavity and upper respiratory tract. J Oral Microbiol. 2015;7:26094. **This study documents abundant environmental microbes in themucosa of the oral cavity and upper airways of healthy human volunteers**.

115. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106:3698–703.

116. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363–72.

117. Nowak EC, de Vries VC, Wasiuk A, Ahonen C, Bennett KA, Le Mercier I, et al. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med. 2012;209:2127–35.

118. Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477–81.

119. Farez MF, Mascanfroni ID, Mendez-Huergo SP, Yeste A, Murugaiyan G, Garo LP, et al. Melatonin contributes to the seasonality ofmultiple sclerosis relapses. Cell. 2015;162:1338–52.

120. Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, et al. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell. 2013;155:1296–308.

121. Zelante T, Iannitti RG, Cunha C, De LA, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balancemucosal reactivity via interleukin-22. Immunity. 2013;39:372–85.

122. Zhang L, Nichols RG, Correll J, Murray IA, Tanaka N, Smith PB, et al. Persistent organic pollutants modify gut microbiota-host metabolic homeostasis in mice through aryl hydrocarbon receptor activation. Environ Health Perspect. 2015;123:679–88.

123. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71.

124. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185:3190–8.

125. Qiu J, Zhou L. Aryl hydrocarbon receptor promotes RORgammat(+) group 3 ILCs and controls intestinal immunity and inflammation. Semin Immunopathol. 2013;35:657–70.

126. Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiotaaccessible carbohydrates. Cell Metab. 2014;20:779–86.

127. Cavaglieri CR, Nishiyama A, Fernandes LC, Curi R, Miles EA, Calder PC. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci. 2003;73:1683–90.

128. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13:2826–32.

129. Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care. 2010;13:715–21.

130. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly Y, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73.

131. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, de Roos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–5.

132. Zeng H, Chi H. Metabolic control of regulatory T cell development and function. Trends Immunol. 2015;36:3–12.

133. Zaccone P, Burton O, Miller N, Jones FM, Dunne DW, Cooke A. Schistosoma mansoni egg antigens induce Treg that participate in diabetes prevention inNOD mice. Eur J Immunol. 2009;39:1098–107.

134. Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13:607–14.

135. Wang Y, Da'Dara AA, Thomas PG, Harn DA. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+)memory and effector cytotoxic T-lymphocyte responses. Immunology. 2010;129:406–17.

136. Stahl B, Thurl S, Zeng J, Karas M, Hillenkamp F, Steup M, et al. Oligosaccharides from human milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem. 1994;223:218–26.

137. Ko AI, Drager UC, Harn DA. A Schistosoma mansoni epitope recognized by a protective monoclonal antibody is identical to the stage-specific embryonic antigen 1. Proc Natl Acad Sci U S A. 1990;87:4159–63.

138. van Liempt E, Bank CM, Mehta P, Garcia-Vallejo JJ, Kawar ZS, Geyer R, et al. Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Lett. 2006;580:6123–31.

139. Adalid-Peralta L, Fragoso G, Fleury A, Sciutto E. Mechanisms underlying the induction of regulatory T cells and its relevance in the adaptive immune response in parasitic infections. Int J Biol Sci. 2011;7:1412–26.

140. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol. 2008;8:142–52.

141. Teitelbaum R, Schubert W, Gunther L, Kress Y, Macaluso F, Pollard JW, et al. The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity. 1999;10:641–50.

142. Fujimura Y. Functionalmorphology ofmicrofold cells (M cells) in Peyer's patches—phagocytosis and transport of BCG by M cells into rabbit Peyer's patches. Gastroenterol Jpn. 1986;21:325–35.

143. Belkaid Y, Segre JA. Dialogue between skin microbiota and immunity. Science. 2014;346:954–9.

144. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337:1115–9.

145. Belkaid Y, Naik S. Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol. 2013;14:646–53.

146.•• Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701–12. **This article provides a comprehensive review on the microbiota-gut-brain and behavior axis.**

147. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34:15490–6.

148.•• Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144:1394–401. **This study provides the first evidence that probiotic administration in healthy humans modifies steady state activity of neural systems controlling cognitive and affective function.**

149. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105:755–64. Curr Envir Health Rpt.

150. Yang H, Zhao X, Tang S, Huang H, Zhao X, Ning Z, et al. Probiotics reduce psychological stress in patients before laryngeal cancer surgery. Asia Pac J Clin Oncol. 2016;12:e92–6.

151. Kato-Kataoka A, Nishida K, Takada M, Suda K, Kawai M, Shimizu K, et al. Fermented milk containing Lactobacillus casei strain Shirota prevents the onset of physical symptoms in medical students under academic examination stress. Benefic Microbes. 2016;7:153–6.

152. O'Brien ME, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, von Pawel J, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol. 2004;15:906–14.

153.• Reber SO, Siebler PH, Donner NC, Morton JT, Smith DG, Kopelman JM, et al. Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice. Proc Natl Acad Sci U S A. 2016. **This study provides the first evidence that immunization with a heatkilled preparation of an environmental immunoregulatory microbe can prevent colitis and reduce anxiety-related behaviors in mice.**

154. Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun. 1998;66:5157–66.

155. Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, Westrich G, et al. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2001;281:G764–78.

156. Collins CH, Grange JM, Yates MD. Mycobacteria in water. J Appl Bacteriol. 1984;57:193–211.

157. Stanford JL, Paul RC. A preliminary report on some studies of environmental mycobacteria from Uganda. Ann Soc Belg Med Trop. 1973;53:389–93.

158. Primm TP, Lucero CA, Falkinham III JO. Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004;17:98–106.

159. Jin BW, Saito H, Yoshii Z. Environmental mycobacteria in Korea. I. Distribution of the organisms. Microbiol Immunol. 1984;28:667–77.

160. Pontiroli A, Khera TT, Oakley BB, Mason S, Dowd SE, Travis ER, et al. Prospecting environmental mycobacteria: combined molecular approaches reveal unprecedented diversity. PLoS One. 2013;8, e68648.

161. Gcebe N, Rutten V, van Pittius NC, Michel A. Prevalence and distribution of non-tuberculous mycobacteria (NTM) in cattle, African buffaloes (Syncerus caffer) and their environments in South Africa. Transbound Emerg Dis. 2013;60 Suppl 1:74–84.

162. Kamala T, Paramasivan CN, Herbert D, Venkatesan P, Prabhakar R. Isolation and identification of environmental mycobacteria in the Mycobacterium bovis BCG trial area of South India. Appl Environ Microbiol. 1994;60:2180–3.

163. Le Bert N, Chain BM, Rook G, Noursadeghi M. DC priming by M. vaccae inhibits Th2 responses in contrast to specific TLR2 priming and is associated with selective activation of the CREB pathway. PLoS One. 2011;6:e18346.

164. Lowry CA, Hollis JH, de Vries A, Pan B, Brunet LR, Hunt JR, et al. Identification of an immune-responsive mesolimbocortical serotonergic system: potential role in regulation of emotional behavior. Neuroscience. 2007;146:756–72.

165. Matthews DM, Jenks SM. Ingestion of Mycobacterium vaccae decreases anxiety-related behavior and improves learning in mice. Behav Process. 2013;96:27–35.

166. Savignac HM, Tramullas M, Kiely B, Dinan TG, Cryan JF. Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav Brain Res. 2015;287:59–72.

167. Savignac HM, Kiely B, Dinan TG, Cryan JF. Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil. 2014;26:1615–27.

168. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010;170:1179–88.

169. Zuo L, Yuan KT, Yu L, Meng QH, Chung PC, Yang DH. Bifidobacterium infantis attenuates colitis by regulating T cell subset responses. World J Gastroenterol. 2014;20:18316–29.

170. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2: 256–61.

171. Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil. 2011;23:1132–9.

172. Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, et al. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology. 2010;139:2102–12.

173. Lopez P, Gonzalez-Rodriguez I, Gueimonde M, Margolles A, Suarez A. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS One. 2011;6, e24776.

174. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974–7.

175. Castillo-Rojas G, Mazari-Hiiart M, de León Ponce S, Amieva-Fernández RI, Agis-Juárez RA, Huebner J, et al. Comparison of Enterococcus faecium and Enterococcus faecalis strains isolated from water and clinical samples: antimicrobial susceptibility and genetic relationships. PLoS One. 2013;8, e59491.

176. Divyashri G, Krishna G, Muralidhara M, Prapulla SG. Probiotic attributes, antioxidant, anti-inflammatory and neuromodulatory effects of probiotic Enterococcus faecium CFR 3003: in vitro and in vivo evidences. J Med Microbiol. 2015;64:1527–40.

177. Bernardeau M, Guguen M, Vernoux JP. Beneficial lactobacilli in food and feed: long-term use, biodiversity and proposals for specific and realistic safety assessments. FEMS Microbiol Rev. 2006;30:487–513.

178. Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1:6.

179. Benton D, Williams C, Brown A. Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr. 2007;61:355–61.

180. Vitali B, Minervini G, Rizzello CG, Spisni E, Maccaferri S, Brigidi P, et al. Novel probiotic candidates for humans isolated from raw fruits and vegetables. Food Microbiol. 2012;31:116–25. Curr Envir Health Rpt.

181. Hammes WP, Vogel RF. The genus Lactobacillus. In: Wood BJB, HolzapfelWH, editors. The genera of lactic acid bacteria. Chapman &Hall; 1995. p. 19–54.

182. Wang T, Hu X, Liang S, Li W,Wu X, Wang L, et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benefic Microbes. 2015;1–11.

183. Perez-Cano FJ, Dong H, Yaqoob P. In vitro immunomodulatory activity of lactobacillus fermentum CECT5716 and Lactobacillus salivarius CECT5713: two probiotic strains isolated from human breast milk. Immunobiology. 2010;215:996–1004.

184. Chung YC, Jin HM, Cui Y, Kim DS, Jung JM, Park JI, et al. Fermented milk of Lactobacillus helveticus IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults. J Funct Foods. 2014;10:465–74.

185. Jia L, Tao W, Shan L, Xu H, Wei L, Feng J. Ingestion of Lactobacillus strain reduces anxiety and improves cognitive function in the hyperammonemia rat. Sci China Life Sci. 2014;57:327–35.

186. Liang S, Wang T, Hu X, Luo J, Li W, Wu X, et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015;310:561–77.

187. Ohland CL, Kish L, Bell H, Thiesen A, Hotte N, Pankiv E, et al. Effects of Lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology. 2013;38:1738–47.

188. Smith CJ, Emge JR, Berzins K, Lung L, Khamishon R, Shah P, et al. Probiotics normalize the gut-brain-microbiota axis in immunodeficient mice. Am J Physiol Gastrointest Liver Physiol. 2014;307:G793–802.

189. Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut. 2011;60:307–17.

190. Rodrigues DM, Sousa AJ, Johnson-Henry KC, Sherman PM, Gareau MG. Probiotics are effective for the prevention and treatment of Citrobacter rodentium-induced colitis in mice. J Infect Dis. 2012;206:99–109.

191. Woo JY, Gu W, Kim KA, Jang SE, Han MJ, Kim DH. Lactobacillus pentosus var. plantarum C29 ameliorates memory impairment and inflammaging in a D-galactose-induced accelerated aging mouse model. Anaerobe. 2014;27:22–6.

192. Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health. 2005;4:25.

193. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115: 1260–7.

194. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108:16050–5.

195. Bloem K, Garcia-Vallejo JJ, Vuist IM, Cobb BA, van Vliet SJ, van Kooyk Y. Interaction of the capsular polysaccharide A from Bacteroides fragilis with DC-SIGN on human dendritic cells is necessary for its processing and presentation to T cells. Front Immunol. 2013;4:103.

196. Shen Y, Giardino Torchia ML, Lawson GW, Karp CL, Ashwell JD, Mazmanian SK. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe. 2012;12:509–20.

197. Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci U S A. 2008;105:19474–9.

198. Gilleron M, Jackson M, Nigou J, Puzo G. Structure, biosynthesis, and activities of the phosphatidyl-myo-inositol-based lipoglycans. In: DafféM, Rayrat J-M, editor. The mycobacterial cell envelope. Washington, DC: ASM Press; 2008. p. 75–105.

199. Ray A, Cot M, Puzo G, Gilleron M, Nigou J. Bacterial cell wall macroamphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie. 2013;95:33–42.

200. Garg A, Barnes PF, Roy S, Quiroga MF, Wu S, Garcia VE, et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur J Immunol. 2008;38: 459–69.

201. Carroll MV, Sim RB, Bigi F, Jakel A, Antrobus R, Mitchell DA. Identification of four novel DC-SIGN ligands on Mycobacterium bovis BCG. Protein Cell. 2010;1:859–70.

202. Quintana FJ, Cohen IR. The HSP60 immune system network. Trends Immunol. 2011;32:89–95.

203. Zanin-Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, Cohen IR. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest. 2006;116: 2022–32.

204. Ohue R, Hashimoto K, Nakamoto M, Furukawa Y, Masuda T, Kitabatake N, et al. Bacterial heat shock protein 60, GroEL, can induce the conversion of naive T cells into a CD4 CD25(+) Foxp3-expressing phenotype. J Innate Immun. 2011;3:605–13.

205. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol. 2005;5:318–30.

206. Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem. 1988;263:15335–41.

207. Takaoka Y, Goto S, Nakano T, Tseng HP, Yang SM, Kawamoto S, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) prevents lipopolysaccharide (LPS)-induced, sepsisrelated severe acute lung injury in mice. Sci Rep. 2014;4:5204.

208. Drage MG, Tsai HC, Pecora ND, Cheng TY, Arida AR, Shukla S, et al. Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of toll-like receptor2. Nat Struct Mol Biol. 2010;17:1088–95. Curr Envir Health Rpt.